This content is from: Patents

MSD licenses first COVID drug to UN patent pool

Molnupiravir is the first COVID-19 product to be licensed to the Medicines Patent Pool since the start of the pandemic

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial